132 related articles for article (PubMed ID: 1648119)
1. Angiotensin converting enzyme system in the normal canine eye: pharmacological and physiological aspects.
Abrams KL; Brooks DE; Laratta LJ; Barnhill MA; Frazier D
J Ocul Pharmacol; 1991; 7(1):41-51. PubMed ID: 1648119
[TBL] [Abstract][Full Text] [Related]
2. Systemic effects resulting from topical ocular administration of SCH 33861, a novel ACE inhibitor ocular hypotensive agent.
Watkins RW; Baum T; Tedesco RP; Pula K; Barnett A
J Ocul Pharmacol; 1988; 4(2):93-100. PubMed ID: 3049862
[TBL] [Abstract][Full Text] [Related]
3. Topical ocular hypotensive effects of the novel angiotensin converting enzyme inhibitor SCH 33861 in conscious rabbits.
Watkins RW; Baum T; Cedeno K; Smith EM; Yuen PH; Ahn HS; Barnett A
J Ocul Pharmacol; 1987; 3(4):295-307. PubMed ID: 3503919
[TBL] [Abstract][Full Text] [Related]
4. Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma.
Shah GB; Sharma S; Mehta AA; Goyal RK
J Cardiovasc Pharmacol; 2000 Aug; 36(2):169-75. PubMed ID: 10942157
[TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin aldosterone profile before and after angiotensin-converting enzyme-inhibitor administration in dogs with angiotensin-converting enzyme gene polymorphism.
Adin D; Atkins C; Domenig O; DeFrancesco T; Keene B; Tou S; Stern JA; Meurs KM
J Vet Intern Med; 2020 Mar; 34(2):600-606. PubMed ID: 32112596
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects.
Lachurié ML; Azizi M; Guyene TT; Alhenc-Gelas F; Ménard J
Circulation; 1995 Jun; 91(12):2933-42. PubMed ID: 7796503
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme activity in human aqueous humor.
Weinreb RN; Sandman R; Ryder MI; Friberg TR
Arch Ophthalmol; 1985 Jan; 103(1):34-6. PubMed ID: 2983647
[TBL] [Abstract][Full Text] [Related]
8. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
[TBL] [Abstract][Full Text] [Related]
9. [Effect of an angiotensin-converting-enzyme inhibitor on the plasma concentration of cytokines and vasoactive molecules in patients with coronary heart disease and hypertension].
Khadartsev AA; Logatkina AV; Terekhov IV; Bondar SS; Bondar NV
Ter Arkh; 2017; 89(12):97-102. PubMed ID: 29411767
[TBL] [Abstract][Full Text] [Related]
10. Interruption of prolonged ramipril treatment in hypertensive patients: effects on the renin-angiotensin system.
Stephan D; Grima M; Welsch M; Barthelmebs M; Vasmant D; Imbs J
Fundam Clin Pharmacol; 1996; 10(5):474-83. PubMed ID: 8902551
[TBL] [Abstract][Full Text] [Related]
11. The effect of enalapril on furosemide-activated renin-angiotensin-aldosterone system in healthy dogs.
Lantis AC; Ames MK; Werre S; Atkins CE
J Vet Pharmacol Ther; 2015 Oct; 38(5):513-7. PubMed ID: 25771846
[TBL] [Abstract][Full Text] [Related]
12. Influence of angiotensin-converting enzyme inhibitor, foroxymithine, on dynamic equilibrium around the renin-angiotensin system in vivo.
Aoyagi T; Wada T; Iinuma H; Ogawa K; Kojima F; Nagai M; Kuroda H; Obayashi A; Umezawa H
J Appl Biochem; 1985 Dec; 7(6):388-95. PubMed ID: 3007425
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme activity in ocular fluids.
Vita JB; Anderson JA; Hulem CD; Leopold IH
Invest Ophthalmol Vis Sci; 1981 Feb; 20(2):255-7. PubMed ID: 6257623
[TBL] [Abstract][Full Text] [Related]
14. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs.
Lantis AC; Ames MK; Atkins CE; DeFrancesco TC; Keene BW; Werre SR
J Vet Pharmacol Ther; 2015 Feb; 38(1):65-73. PubMed ID: 25224804
[TBL] [Abstract][Full Text] [Related]
16. Hypotensive effect of SA446, an angiotensin converting enzyme inhibitor, in 2-kidney, 1-clip renal hypertensive and normotensive dogs.
Nishimura K; Miyazaki M; Okunishi H; Toda N
Jpn J Pharmacol; 1987 Apr; 43(4):379-87. PubMed ID: 3039218
[TBL] [Abstract][Full Text] [Related]
17. [What have we learned from converting enzyme inhibitors on renin-angiotensin system?].
Waeber B; Nussberger J; Brunner HR
Rev Prat; 1992 Dec; 42(20):2529-32. PubMed ID: 1338608
[TBL] [Abstract][Full Text] [Related]
18. Local ocular renin-angiotensin-aldosterone system: any connection with intraocular pressure? A comprehensive review.
Holappa M; Vapaatalo H; Vaajanen A
Ann Med; 2020 Aug; 52(5):191-206. PubMed ID: 32308046
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone:creatinine, after pharmacologic provocation) and the response to ACE inhibition.
Ames MK; Atkins CE; Lantis AC; zum Brunnen J
J Renin Angiotensin Aldosterone Syst; 2016; 17(1):1470320316633897. PubMed ID: 27009288
[TBL] [Abstract][Full Text] [Related]
20. New perspectives in the renin-angiotensin-aldosterone system (RAAS) I: endogenous angiotensin converting enzyme (ACE) inhibition.
Fagyas M; Úri K; Siket IM; Daragó A; Boczán J; Bányai E; Édes I; Papp Z; Tóth A
PLoS One; 2014; 9(4):e87843. PubMed ID: 24691160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
